For laboratory and research use only. Not for human consumption.

Journal/Science

· 12 min read

503A vs 503B Compounding: The Difference, and What It Means for Peptides

Educational content only. Not medical advice. FeelGood does not claim that any peptide treats, cures, prevents, or mitigates any disease or condition. Consult a qualified healthcare provider before making any decisions about peptide therapy.

Two kinds of compounder can legally make a drug that an ordinary manufacturer does not: a 503A compounding pharmacy and a 503B outsourcing facility. The two are often treated as interchangeable, but they answer to different laws, different regulators, and two separate lists of permitted bulk substances. For peptides, that distinction decides what can be compounded at all. This page sets the two pathways side by side, explains the two bulks lists, and works through a 2026 example that shows why the difference matters. For what a 503A pharmacy is on its own, see the 503A compounding pharmacy explainer. For where each peptide sits on the 503A list, see the 503A bulks-list status board. For the July 2026 review that may change the 503A side, see the PCAC meeting explainer.

This sits within the wider question of peptide legality. For how United States law treats peptides overall, see the overview on whether peptides are legal.

503A vs 503B at a glance

The two pathways differ on almost every axis. The summary below is the short version; the sections that follow explain each line.

The legal split: section 503A and section 503B

The two pathways were created sixteen years apart, in response to different problems. Section 503A was added by the FDA Modernization Act of 1997 and codified traditional pharmacy compounding: a pharmacist preparing a tailored medication against a prescription for a specific patient. [2]

Section 503B was added by the Drug Quality and Security Act of 2013, enacted after a 2012 fungal-meningitis outbreak traced to a compounding pharmacy that was producing sterile drugs at industrial scale without manufacturer-level controls. The outbreak caused more than sixty deaths. Congress created a new, voluntary category, the outsourcing facility, that may compound larger batches without patient-specific prescriptions in exchange for registering with the FDA and meeting manufacturer-grade quality requirements. [2] The two sections therefore describe two different trades: 503A is individualized pharmacy practice, and 503B is regulated batch production.

Two separate bulks lists, not one

The single most misunderstood point is that there are two lists, governed by two different standards. A substance permitted under one pathway is not automatically permitted under the other.

On the 503A side, a bulk drug substance qualifies only if one of three conditions is met: it has a USP or NF monograph, it is a component of an FDA-approved drug, or it appears on the 503A bulks list codified at 21 CFR 216.23. [5] That codified list is small. It currently names six substances, none of them peptides, so the larger working set of substances a 503A pharmacy may use rests on the monograph and approved-drug conditions rather than on the finalized list itself.

On the 503B side, an outsourcing facility may use a bulk drug substance only if the FDA has determined there is a clinical need to compound from that bulk substance, which places it on the 503B bulks list, or the drug is on the FDA drug-shortage list. [6] The clinical-need standard is deliberately strict. The FDA does not treat supply convenience, cost, or backorder as clinical need; it asks whether there is a medical reason a product must be compounded from the bulk substance rather than supplied as an approved drug.

Because the two lists rest on different tests, the practical question for any substance, including any peptide, is not whether it can be compounded in the abstract but which list, if either, it sits on.

Patient-specific versus office stock

The prescription requirement is the dividing line that matters most in practice. A 503A pharmacy compounds against a valid prescription written for an identified patient. It cannot lawfully produce large quantities to hold as stock. A 503B outsourcing facility may produce batches in advance and supply them to clinics and provider offices without a prescription for each unit, the arrangement usually called office stock. [2] That single difference explains most of the others: batch production for unknown future patients is why 503B carries manufacturer-grade obligations, and individual preparation is why 503A does not.

Oversight and quality: USP chapters versus cGMP

The two quality regimes differ in kind rather than in strictness. A 503A pharmacy is licensed by its state board of pharmacy and follows the United States Pharmacopeia compounding chapters: 795 for non-sterile preparations, 797 for sterile preparations, and 800 for hazardous drugs. Within the conditions of section 503A, it is statutorily exempt from current good manufacturing practice. [3]

A 503B outsourcing facility registers directly with the FDA, is subject to risk-based FDA inspection, and must comply with current good manufacturing practice under 21 CFR Parts 210 and 211, the same framework that governs commercial drug manufacturers. [4] Its drugs gain certain exemptions, such as from new-drug-approval requirements, but never from current good manufacturing practice. One consequence is beyond-use dating: a 503A preparation carries a shorter date set by the USP chapters, while a 503B product can carry a longer date supported by stability testing conducted under current good manufacturing practice.

Is 503A or 503B "safer"?

The question is common, and the honest answer is that the pathways carry different controls and different risks rather than a single ranking. A 503B facility operates under manufacturer-grade process controls and FDA inspection, which is well suited to sterile, high-volume production. A 503A pharmacy operates under USP standards and state oversight, which is suited to individualized preparation against a specific prescription. A batch of office stock and a single patient-specific preparation are not the same product made to two grades; they are different activities, each with a control regime built for it. The useful comparison is therefore between the regime and the use, rather than a verdict that one ranks higher than the other.

What each pathway means for peptide availability

For research peptides, the two lists point to the same conclusion from two directions. Most research peptides, including BPC-157, KPV, TB-500, and MOTs-C, have no USP or NF monograph, are not components of any FDA-approved drug, and do not appear on the 503A bulks list, so they do not meet the 503A conditions. The same peptides are not on the 503B bulks list and are not on the shortage list, and none is the active ingredient of an approved drug, so they do not meet the 503B conditions either. Neither pathway reaches them.

The 503A side is also under active review. BPC-157 currently sits in the FDA's interim Category 2 for nominated 503A substances, the bucket for substances flagged with significant safety concerns, and the Pharmacy Compounding Advisory Committee is scheduled to review BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, and Epitalon on July 23 and 24, 2026. [7] Where each of those peptides stands on the 503A side is tracked in the 503A bulks-list status board, and the meeting itself is covered in the PCAC explainer. The point for this comparison is narrower: a peptide's availability depends on which list it reaches, and as of mid-2026 the research peptides reach neither.

A 2026 example: how a 503B exclusion hits one list, not the other

A current FDA action shows the two lists moving independently. On May 1, 2026, the FDA published a Federal Register notice (91 FR 23431, document number 2026-08552, docket FDA-2018-N-3240) proposing not to include semaglutide, tirzepatide, and liraglutide, the active ingredients in several GLP-1 drugs, on the 503B bulks list. The agency found no clinical need for outsourcing facilities to compound them from bulk now that the products are no longer in shortage. The comment period closed in late June 2026. [8] As a proposal, it changes nothing unless finalized; if finalized, outsourcing facilities could not compound those drugs from the bulk substance.

What makes the action a useful illustration is its reach. It targets the 503B list specifically. Regulatory analysts noted that, by itself, it would not bar 503A pharmacies from compounding those drugs, because a 503A pharmacy can compound using the active ingredient drawn from an approved product rather than from a listed bulk substance. [8] That asymmetry comes with an important caveat, however. Semaglutide and tirzepatide were removed from the FDA shortage list in 2025, and section 503A separately restricts compounding a drug that is essentially a copy of a commercially available product. Routine 503A compounding of these GLP-1 drugs is therefore already heavily restricted, permitted only where an individual patient has a documented medical need, such as a clinically justified formulation difference. The lesson is structural rather than about GLP-1 drugs in particular: availability follows the specific list, and the two lists are changed by separate actions on separate timelines.

How to check which list a substance is on

The current status of any substance can be confirmed from FDA primary sources. The 503A bulks list is codified at 21 CFR 216.23 and available through the eCFR. The FDA's "Bulk Drug Substances Used in Compounding under Section 503A" materials carry the interim category placements. The 503B bulks list and its clinical-need notices are published on the FDA's 503B materials and in the Federal Register, such as the May 2026 notice above. The FDA also publishes a list of registered outsourcing facilities, which confirms whether a given 503B facility is in good standing. A substance not found on either bulks list, and not a component of an approved drug, is not compoundable on that basis under either pathway.

Frequently asked questions

What is the difference between 503A and 503B compounding? A 503A pharmacy compounds individualized preparations against a patient-specific prescription, is licensed by a state board of pharmacy, and follows USP compounding standards. A 503B outsourcing facility produces batches without patient-specific prescriptions, registers with the FDA, and complies with current good manufacturing practice. They operate under two different sections of the FD&C Act and two separate bulks lists. [1] [2]

Is 503A or 503B safer? Neither label is a safety ranking. The two pathways carry different control regimes for different activities: 503B uses manufacturer-grade controls and FDA inspection suited to batch production, while 503A uses USP standards and state oversight suited to individualized compounding. The meaningful question is whether the regime fits the use. [3] [4]

What is the 503B bulks list? It is the list of bulk drug substances the FDA has determined there is a clinical need to compound at outsourcing facilities. A substance not on that list, and not on the drug-shortage list, cannot be used by a 503B facility. It is separate from, and stricter than, the 503A bulks list. [6]

What is the 503A bulks list, and how is it different from the 503B bulks list? The 503A bulks list (21 CFR 216.23) is one of three ways a substance can qualify for 503A compounding, alongside having a USP or NF monograph or being a component of an approved drug. The 503B bulks list is a separate list built on an FDA clinical-need determination. The same substance can qualify under one pathway and not the other. [5] [6]

Are peptides on the 503A or 503B bulks list? As of mid-2026, the research peptides in wide circulation are on neither. They have no monograph, are not components of approved drugs, and have no clinical-need determination. Several are under 503A review at the July 2026 advisory meeting, but none is finalized on either list. [5] [7]

Can a 503A pharmacy compound something a 503B facility cannot, or vice versa? Yes. Because the two pathways rest on different conditions and different lists, a substance can be available to one and not the other. The 2026 GLP-1 proposal is an example: it would remove a 503B route for those drugs while leaving the narrower 503A route governed by separate rules. [8]

Sources

  1. Cornell Law School, Legal Information Institute. 21 U.S.C. 353a (section 503A) and 21 U.S.C. 353b (section 503B). https://www.law.cornell.edu/uscode/text/21/353a and https://www.law.cornell.edu/uscode/text/21/353b
  2. Congressional Research Service. "Drug Compounding: FDA Authority and Possible Issues for Congress," report R45069 (statutory history: FDAMA 1997 added section 503A; the 2012 NECC outbreak; the Drug Quality and Security Act of 2013 added section 503B and the outsourcing-facility category). https://www.congress.gov/crs-product/R45069
  3. United States Pharmacopeia. "Recognition of USP Compounding Standards" (USP chapters 795, 797, and 800; the 503A standards framework). https://www.usp.org/compounding/legal-considerations
  4. Food and Drug Administration. "Information for Outsourcing Facilities" (503B registration and current good manufacturing practice, 21 CFR Parts 210 and 211). https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities
  5. Electronic Code of Federal Regulations. 21 CFR 216.23, the 503A bulks list. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23
  6. Food and Drug Administration. "List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the FD&C Act." Federal Register, May 1, 2026, 91 FR 23431, document 2026-08552, docket FDA-2018-N-3240. https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
  7. Food and Drug Administration. "Pharmacy Compounding Advisory Committee; Notice of Meeting," July 23 and 24, 2026, docket FDA-2025-N-6895. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
  8. Orrick. "FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs" (the 503B proposal and its limited effect on 503A); corroborated by Medical News Today, "FDA proposes to ban bulk compounding of semaglutide, tirzepatide" (May 10, 2026). https://www.orrick.com/en/Insights/2026/05/FDA-Moves-to-Shut-the-Door-on-Large-Scale-Compounding-of-GLP1-Drugs

We publish the science, not a sales pitch.

The FeelGood Journal is a citation-led editorial library on peptide research, manufacturing standards, and the regulatory landscape, written for readers who want primary sources.

Back to the Journal